Clinical trial
A Randomized Double-blind, Four-Arm Active and Placebo-controlled Dose-Finding Trial to Evaluate the Efficacy, Tolerability, Safety and Dose Response of LYT-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
NCT05321420 is registered in ClinicalTrials.gov with PureTech as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized Double-blind, Four-Arm Active and Placebo-controlled Dose-Finding Trial to Evaluate the Efficacy, Tolerability, Safety and Dose Response of LYT-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
- Lead sponsor
- PureTech
- Phase
- Phase 2
- Overall status
- Active, not recruiting
- Start date
- July 22, 2022
- Completion date
- December 31, 2025
- Enrollment
- 240 (estimated)
- Sites
- 103
Conditions
As the registry lists them; a condition with its own page is linked.